TWI871539B - 可保存之調配物 - Google Patents

可保存之調配物 Download PDF

Info

Publication number
TWI871539B
TWI871539B TW111142719A TW111142719A TWI871539B TW I871539 B TWI871539 B TW I871539B TW 111142719 A TW111142719 A TW 111142719A TW 111142719 A TW111142719 A TW 111142719A TW I871539 B TWI871539 B TW I871539B
Authority
TW
Taiwan
Prior art keywords
concentration
composition
insulin
phenol
bif
Prior art date
Application number
TW111142719A
Other languages
English (en)
Chinese (zh)
Other versions
TW202339790A (zh
Inventor
大衛 保羅 艾倫
約翰 麥可 比爾斯
文森 約翰 寇維立
派翠克 丹尼爾 唐納文
肯 康宜 錢
王薇
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202339790A publication Critical patent/TW202339790A/zh
Application granted granted Critical
Publication of TWI871539B publication Critical patent/TWI871539B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111142719A 2021-11-15 2022-11-09 可保存之調配物 TWI871539B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163279390P 2021-11-15 2021-11-15
US63/279,390 2021-11-15

Publications (2)

Publication Number Publication Date
TW202339790A TW202339790A (zh) 2023-10-16
TWI871539B true TWI871539B (zh) 2025-02-01

Family

ID=84537390

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142719A TWI871539B (zh) 2021-11-15 2022-11-09 可保存之調配物

Country Status (19)

Country Link
US (1) US20250000950A1 (https=)
EP (1) EP4433024A1 (https=)
JP (1) JP2024543457A (https=)
KR (1) KR20240082407A (https=)
CN (1) CN118302152A (https=)
AR (1) AR127619A1 (https=)
AU (1) AU2022386352B2 (https=)
CA (1) CA3238180A1 (https=)
CL (1) CL2024001415A1 (https=)
CO (1) CO2024006121A2 (https=)
CR (1) CR20240202A (https=)
DO (1) DOP2024000084A (https=)
EC (1) ECSP24036789A (https=)
IL (1) IL312623A (https=)
JO (1) JOP20240108A1 (https=)
MX (1) MX2024005879A (https=)
PE (1) PE20241354A1 (https=)
TW (1) TWI871539B (https=)
WO (1) WO2023086980A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097584B2 (en) * 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
US20220354782A1 (en) * 2019-09-17 2022-11-10 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin and glucagon formulations and methods of administration
WO2021119607A1 (en) * 2019-12-13 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme

Also Published As

Publication number Publication date
TW202339790A (zh) 2023-10-16
JOP20240108A1 (ar) 2024-05-14
KR20240082407A (ko) 2024-06-10
ECSP24036789A (es) 2024-06-28
PE20241354A1 (es) 2024-07-03
MX2024005879A (es) 2024-05-29
CR20240202A (es) 2024-06-11
CL2024001415A1 (es) 2024-10-18
CN118302152A (zh) 2024-07-05
DOP2024000084A (es) 2024-06-16
EP4433024A1 (en) 2024-09-25
AU2022386352A1 (en) 2024-05-09
AR127619A1 (es) 2024-02-14
IL312623A (en) 2024-07-01
JP2024543457A (ja) 2024-11-21
US20250000950A1 (en) 2025-01-02
WO2023086980A1 (en) 2023-05-19
CO2024006121A2 (es) 2024-06-27
AU2022386352B2 (en) 2025-12-18
CA3238180A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
KR101084412B1 (ko) 코팅된 제약 용기 내 안정화된 액상 단백질 제제
EP3140008B1 (en) Rapid-acting insulin compositions
EP2586459B1 (en) Vegf antagonist formulations
US12577297B2 (en) Anti-IL-23p19 antibody formulations
JP2011068694A (ja) 安定な液体インターフェロン処方物
JP2003504346A (ja) 成長ホルモン製剤
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
TWI871539B (zh) 可保存之調配物
JP2010536906A (ja) Ｇ−ｃｓｆの液体製剤
HK40077155A (en) A lyophilised pharmaceutical formulation and its use
JP2002371009A (ja) 顆粒球コロニー刺激因子の薬理効果の持続時間延長方法
HK1228824B (en) Rapid-acting insulin compositions
HK1228824A1 (en) Rapid-acting insulin compositions